| Ytd | 35.04% | |
| 1y | 30.28% |
| Open | 1.84 | Prev Close | 1.85 | Low | 1.83 | High | 1.86 | Mkt Cap | 451.16M |
| Vol | 370.56K | Avg Vol | 8.14M | EPS | -0.77 | P/E | -2.40 | Forward P/E | -1.50 |
| Beta | 0.46 | Short Ratio | 11.46 | Inst. Own | 80.20% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 2.02 | 200-d Avg | 1.85 | 1yr Est | 9.04 |
ALLO News
ALLO-316 Achieved a 31% Confirmed Response Rate with the Recommended Phase 2 Regimen in Patients wit
Allogene Therapeutics offers upside potential driven by the pivotal ALPHA3 trial for Cema-cel in fir
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?
SOUTH SAN FRANCISCO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: A
SOUTH SAN FRANCISCO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: A
ALLO posts a narrower Q1 loss, raises its 2026 expense outlook and shares positive interim data from
Biotech dealmaking accelerated heading into the JPM 2026 Healthcare Conference as large drugmakers f
Allogene Therapeutics, Inc. (ALLO) Q1 2026 Earnings Call Transcript
Allogene Therapeutics NASDAQ: ALLO said its first quarter of 2026 was marked by early clinical progr
Allogene Therapeutics said on Wednesday it has ended a key partnership for ​developing cell therapie
SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: A
Conference Call and Webcast Scheduled for May 13, 2026 at 2 p.m. PT/5 p.m. ET SOUTH SAN FRANCISCO, C
SOUTH SAN FRANCISCO, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq:
SOUTH SAN FRANCISCO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq:
Allogene Therapeutics, Inc. (NASDAQ: ALLO - Get Free Report) shares shot up 13.1% during mid-day tra
SOUTH SAN FRANCISCO, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq:
U.S. stocks were mixed on Thursday, with the Dow Jones gaining 0.1%. Aehr Test Systems shares rose 1
Analysts change outlook on top names: Mizuho downgrades PYPL, B of A increases CIEN PT, Needham rais
SOUTH SAN FRANCISCO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq:
SOUTH SAN FRANCISCO, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq:
Allogene jumps as cema-cel shows strong MRD clearance and safety in the ALPHA3 study, signaling pote
US stock futures mixed, Nasdaq 100 up over 50 points. JPMorgan shares down 3.1% after beating earnin
Top Wall Street analysts have changed their outlook on top names. For full analyst rating changes, i
Allogene Therapeutics, Inc. (NASDAQ: ALLO - Get Free Report) was the target of some unusual options
U.S. stocks were mixed on Monday, with the Dow Jones falling over 200 points. Leggett & Platt ro
IDEAYA Biosciences shares (NASDAQ: IDYA) jumped 18% in pre-market trading after announcing topline
U.S. stock futures lower, Dow futures down 300 points. Worthington Steel Inc (NYSE: WS) shares fall
Stocks fall, Nasdaq drops 200 points. Apogee Therapeutics (APGE) rises 19.4% on positive trial data.
U.S. stocks higher as Dow Jones gains 300 points; El Pollo LoCo Holdings jumps 17.6% on better-than-
 On Tuesday, 647 companies set new 52-week lows.
 During the session on Thursday, 461 stocks hit new 52-week lows.
Companies Reporting Before The Bell • Nomura Holdings (NYSE:NMR) is likely to report earnings for i
 On Friday, 431 companies hit new 52-week lows.
  Tuesday's session saw 729 companies set new 52-week lows.
 Companies Reporting Before The Bell • DISH Network (NASDAQ:DISH) is likely to report quarterly e
Stocks That Hit 52-Week Lows On Monday